SREBP-2, a new target of metformin?

BACKGROUND: Metformin, as the first-line treatment anti-diabetic drug, represents increasing evidence of a potential efficacy in improving dyslipidemia. However, the exact molecular mechanism(s) by which metformin influences lipid metabolism remains incompletely understood. METHODS: The HepG2 cells...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drug Des Devel Ther
Main Authors: Zhang, Fengxia, Sun, Wenxiu, Chen, Jianbo, Jiang, Lusheng, Yang, Ping, Huang, Yufang, Gong, Aihua, Liu, Shudong, Ma, Shizhan
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6287532/
https://ncbi.nlm.nih.gov/pubmed/30584280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S190094
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados